Small RNA seq of HepG2 cells expressing shRNA targeting wild-type, mutated or both ß-catenin versus shRNA control
HepG2 cells expressing doxycycline-inducible shRNA were treated by doxycycline for 7 days.  Four stable cell lines were used: HepG2 cells expressing a control shRNA; HepG2 cells expressing a shRNA targeting wild-type ß-catenin ; HepG2 cells expressing a shRNA targeting mutated ß-catenin ; HepG2 cells expressing a shRNA targeting both wild-type  and mutated ß-catenin. Small RNAs were sequenced on an illumina NextSeq 2000 sequencer.